New GSK WKN: A3DMB5 ISIN: GB00BN7SWP63 Forum: Aktien User: o2kuh
23,13
EUR
-0,56 % -0,13
22:47:31 Uhr,
Lang & Schwarz
Kommentare 704
d
der_weisnix,
5. Feb 20:52 Uhr
0
Sehr stark heute wieder…
n
nadu4u,
5. Feb 16:07 Uhr
0
+3%
n
nadu4u,
5. Feb 16:07 Uhr
0
25 €
n
nadu4u,
5. Feb 15:45 Uhr
0
+2,7%
n
nadu4u,
5. Feb 15:45 Uhr
0
24,8 €
n
nadu4u,
4. Feb 19:31 Uhr
0
+8%
n
nadu4u,
4. Feb 19:31 Uhr
0
24,3 €
d
der_weisnix,
4. Feb 14:33 Uhr
0
Wenn das so weitergeht schaffen wir bald die 25€ 💪
o
o2kuh,
4. Feb 12:33 Uhr
0
23,71 EUR
+5,03 % +1,14
n
nadu4u,
4. Feb 10:34 Uhr
0
Was hat sich da getan?
n
nadu4u,
4. Feb 10:34 Uhr
0
Seit Oktober extrem stark
d
der_weisnix,
4. Feb 10:30 Uhr
0
💪
n
nadu4u,
4. Feb 10:29 Uhr
0
+3%
n
nadu4u,
4. Feb 10:29 Uhr
0
23,1 €
Guru123,
4. Feb 8:52 Uhr
0
Total 2025 sales £32.7 billion +4% AER; +7% CER
Specialty Medicines sales £13.5 billion (+17%); Respiratory, Immunology & Inflammation £3.8 billion (+18%); Oncology
£2.0 billion (+43%); HIV sales £7.7 billion (+11%)
Vaccines sales £9.2 billion (+2%); Shingrix £3.6 billion (+8%); Meningitis vaccines £1.6 billion (+12%); and Arexvy £0.6
billion (+2%)
General Medicines sales £10.0 billion (-1%); Trelegy £3.0 billion (+13%)
Total operating profit >100% and Total EPS >100% driven by lower Significant legal expenses, lower CCL charges and
higher other operating income, partly offset by intangible asset impairments
Core operating profit +11% and Core EPS +12% reflecting Specialty Medicines and Vaccines growth, SG&A productivity,
higher royalty income and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines
Cash generated from operations of £8.9 billion with free cash flow of £4.0 billion
Strong pipeline progress in 2025:
5 major FDA approvals: Blenrep, Exdensur, Nucala COPD, Penmenvy, Blujepa
7 pivotal trial starts including: risvutatug rezetecan (ris-rez) for 2L/3L ES-SCLC; efimosfermin in MASH; Exdensur for COPD; and velzatinib for 2L GIST
Q4 2025 dividend of 18p declared; 66p FY 2025; 70p expected for full year 2026
£1.4 billion executed to date as part of the £2 billion share buyback programme announced at FY 2024
2026 guidance and 2031 sales outlook reaffirmed
Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9%
2031 sales outlook of more than £40 billion
d
der_weisnix,
3. Feb 16:15 Uhr
0
Nur kein Stress hier, das wird schon…
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | Investmentchancen | -3,39 % | |
| 2 | Beyond Meat Hauptdiskussion | +2,30 % | |
| 3 | BLOOM ENERGY A Hauptdiskussion | +4,02 % | |
| 4 | BAYER Hauptdiskussion | -2,74 % | |
| 5 | für alle, die es ehrlich meinen beim Traden. | ||
| 6 | NVIDIA Hauptdiskussion | +4,34 % | |
| 7 | Critical Infrastructure Technologies Hauptdiskussion | ±0,00 % | |
| 8 | Critical Metals: Grönland - Tanbreez seltene Erden | +23,82 % | |
| 9 | EUROPEAN LITHIUM Hauptdiskussion | +56,09 % | |
| 10 | DAX Hauptdiskussion | -0,64 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | Investmentchancen | -3,39 % | |
| 2 | Beyond Meat Hauptdiskussion | +2,30 % | |
| 3 | BLOOM ENERGY A Hauptdiskussion | +4,02 % | |
| 4 | BAYER Hauptdiskussion | -2,74 % | |
| 5 | NVIDIA Hauptdiskussion | +4,34 % | |
| 6 | Critical Infrastructure Technologies Hauptdiskussion | ±0,00 % | |
| 7 | Critical Metals: Grönland - Tanbreez seltene Erden | +23,82 % | |
| 8 | EUROPEAN LITHIUM Hauptdiskussion | +56,09 % | |
| 9 | Novo Nordisk nach Split | +0,77 % | |
| 10 | DeFi Technologies: Eine Perle? | -2,61 % | Alle Diskussionen |